Stoke Therapeutics Inc.

As the first Dravet syndrome products establish the market, the pipeline moves toward selective small molecules and genetic therapies

As regulatory hurdles push early-stage trials out of the U.S., three things FDA can do to bring them back

Plus: Antithrombotic comes back to Novartis via deal for Anthos, Newleos debuts with portfolio of Roche assets, and more

Danish pharma eyeing growth beyond loss of exclusivity for Rexulti, aiming for broad label in rare epilepsies

Plus: Oppenheimer promotes Margolis; Biofidelity and Annexon each announce trio of hires; and Aura gets a new SVP

Plus: Stoke hires Thomas Leggett as CFO, and updates from TScan, Rinri, Tevogen and more

Plus: Foghorn hires Humer and updates from Javelin, Stoke, Sensorium, Theradaptive and more

Plus: A PIPE for CervoMed ahead of dementia readout; and Stoke, Praxis follow clinical readouts with opportunistic follow-ons

Plus readouts for Nanoscope, Axsome, Chugai, Acelyrin and Nkarta

Plus: Stoke falls on Dravet update and updates from Astellas-PeptiDream, Kiniksa and A-Alpha